Low Dose Naltrexone (LDN) has been reported anecdotally to reduce the symptoms of
Fibromyalgia, a Chronic Multisystem Illness. The drug may work by regulating natural
pain-reducing systems. In this study, we will administer both LDN and placebo to a small
group of individuals with Fibromyalgia and Gulf War Syndrome, both Chronic Multisymptom
Illnesses, to assess the drug's efficacy in treating the condition.
This study will be a placebo-controlled, double-blind, cross-over drug tria. Patients with
Primary Fibromyalgia or Gulf War Syndrome will be recruited from the Stanford University
Pain Management Center and the surrounding community. Participation in the study will cover
22 weeks. Participants will attend a laboratory session 12 times for progress checkups, and
will complete daily measures of symptoms.
Currently suffering from moderate to severe Fibromyalgia or symptoms of Gulf War Syndrome
Age 18-65. Not taking any opioid analgesic Not pregnant or planning to become pregnant.
Any known allergy to naltrexone or naloxone. Actual or planned pregnancy.